SCHEMBL7164282

SCHEMBL7164282

CC(O)(P(=O)(O)O)P(=O)(O)Oc1cccc(I)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 2/20 0.36
TP53BP1 Q12888 1/20 0.35
LMNA P02545 1/20 0.35
GGPS1 O95749 2/20 0.34
MTOR P42345 1/20 0.33
PTPRC P08575 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
KDM4E B2RXH2 1/20 0.32
FDPS P14324 1/20 0.32
PTPN5 P54829 1/20 0.32
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GRM5 P41594 1/20 0.31
PTPN2 P17706 1/20 0.31
PTPN1 P18031 1/20 0.31
PTPRB P23467 1/20 0.31
PTPN6 P29350 1/20 0.31
PTPN11 Q06124 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5897154 0.80 SRC (0.53) SRCLMNAMEN1KMT2AFDPS
SCHEMBL7165035 0.79 ACHE (0.40) SRCLMNAGGPS1PTPRCMEN1
SCHEMBL4679260 0.73 FDPS (0.44) LMNAKMT2AFDPSALDH1A1
Water SCHEMBL5177023 0.72 FDPS (0.43) LMNAKMT2AFDPSALDH1A1
SCHEMBL13301849 0.69 LMNA (0.35) SRCLMNAMEN1KMT2AHDAC1
SCHEMBL22619019 0.67 MEN1 (0.47) MEN1KMT2AHDAC1HDAC2
SCHEMBL4189787 0.65 KIF11 (0.41) TP53BP1MEN1KMT2AKDM4EALDH1A1
SCHEMBL16753741 0.64 PLG (0.41) TP53BP1TBXA2R
SCHEMBL16456183 0.64 ELANE (0.51) TP53BP1LMNAMEN1KMT2ATBXA2R
SCHEMBL505384 0.63 CYP2C19 (0.50) SRCLMNAMEN1KMT2APTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6548042-B2 Such as tetraethyl-N-(m-trimethylsilylphenylethyl)amino-methylenebisphosphonate for palliative and curative treatment of bone disorders and breast cancer ARSTAD ERIK (NO) 2003-04-15 US disclosed
US-20020042539-A1 Bis-phosphonate compounds ARSTAD ERIK (NO) 2002-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042539-A1 Bis-phosphonate compounds PHOSPHO1, PTMS, PTEN SRC 531/4885TP53BP1 2114/4885LMNA 3203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.